Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Recursion Pharmaceuticals's total inventories for the quarter that ended in Jun. 2026 was MXN0.0 Mil. Recursion Pharmaceuticals's average total inventories from the quarter that ended in Mar. 2026 to the quarter that ended in Jun. 2026 was MXN0.0 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Recursion Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was MXN8.10.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Recursion Pharmaceuticals's Days Inventory for the
three
months ended in Jun. 2026 was 0.00.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Recursion Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.00.
Recursion Pharmaceuticals (MEX:RXRX) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Recursion Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Recursion Pharmaceuticals's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Recursion Pharmaceuticals Total Inventories Related Terms
Recursion Pharmaceuticals Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recursion Pharmaceuticals Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Recursion Pharmaceuticals (MEX:RXRX) has a Total Inventories of MXN0.0 Mil as of Jun. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Recursion Pharmaceuticals and its competitors.
Is Recursion Pharmaceuticals' Total Inventories too high?
Recursion Pharmaceuticals' current Total Inventories is MXN0.0 Mil. Overall, Recursion Pharmaceuticals has a GF Score™ of 43/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' Total Inventories compare to INVA and TSHA?
Recursion Pharmaceuticals' Total Inventories of MXN0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Recursion Pharmaceuticals and its competitors. Recursion Pharmaceuticals's current Total Inventories is MXN0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (MEX:RXRX) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN50.45, compared to a current price of MXN59.09 — trading 17.1% above its estimated fair value. The current Total Inventories is MXN0.0 Mil. Recursion Pharmaceuticals' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Recursion Pharmaceuticals (MEX:RXRX), the current Total Inventories is MXN0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recursion Pharmaceuticals (MEX:RXRX) Overvalued in 2026?
Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN59.09 is trading 17.1% above its estimated GF Value™ of MXN50.45.
GuruFocus considers Recursion Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for MEX:RXRX:
Total Inventories: MXN0.0 Mil
GF Value™: MXN50.45 vs. price of MXN59.09 (17.1% above fair value)
No single metric tells the full story. See the MEX:RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
43GF Score
Get the complete analysis for MEX:RXRX
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RXRX has been successfully added to your 
